Dr. Abdulai joined Sanofi in 2018 where she serves as a clinical research director for the Immunology and Inflammation (I&) division. In addition to her drug development work, she acts as a digital enabler and works to advance the Sanofi digital health strategy within I&I. This includes advancing technology in R&D that transforms the product life cycle for faster and more efficient clinical trials: integrating real world data to identify the right patient population, using analytics to drive new indications, and incorporating wearables and digital tools into clinical trials. Dr. Abdulai has a Master of Medical Science in Biomedical Informatics from Harvard Medical School. She attended medical school at Howard University College of Medicine, completed internal medicine training at the Mayo Clinic in Rochester, MN and Pulmonary and Critical Care fellowship at Brigham and Women's Hospital in Boston, MA. She is triple board certified and continues to practice by volunteering at a Boston-based community health center where she treats patients with asthma and chronic obstructive pulmonary disease. While in medical school, Dr. Abdulai co-founded the New Freedmen’s clinic to provide free holistic care to the uninsured and underinsured local population. In 2009, Dr. Abdulai was featured in O! Oprah Magazine as one of 80 inspiration women entrepreneurs from around the country for the O! Oprah Magazine-White House Project Leadership Conference. Among her many other honors, Dr. Abdulai was invited to the White House for President Obama’s Innovative Programs Summit which highlighted impactful social entrepreneurship programs across the country. Her passions including increasing access to clinical trials for women and people of color. Her personal project into this area was chosen for the Harvard iLab Venture Incubation Program in 2016.

Governor Charlie Baker was sworn in for a second term as the 72nd Governor of the Commonwealth of Massachusetts on January 3, 2019, after a first term focused on moving Massachusetts forward through bipartisan, results-driven leadership. Governor Baker has used public private partnerships to spur economic development, reformed the state’s regulatory environment, and delivered critical tax relief by doubling the Earned Income Tax Credit. Ensuring Massachusetts continues to be a national leader in education, Governor Baker has made historic investments in K-12 education, increased support for vocational and technical schools, and expanded early college opportunities for high school students. Governor Baker has put Massachusetts at the forefront of fighting the opioid and heroin epidemic, doubling spending on prevention, education, treatment, and recovery and signing two major bills that have served as models for other states. Confronted with the challenges of rising energy costs and a changing climate, Governor Baker has taken nation-leading steps to diversify the Commonwealth’s energy portfolio, safeguard residents, municipalities and businesses from the impacts of climate change, and secure progress toward greenhouse gas reduction targets. Governor Baker has spearheaded long overdue reforms at the MBTA that have led to significant improvements to operations and finances, and put the T on track to spend more than $8 billion on infrastructure over the next five years to improve riders’ experience. Prior to his election, Governor Baker was a highly successful leader of complex business and government organizations, serving as a cabinet secretary to both Governor William Weld and Paul Cellucci, and leading Harvard Pilgrim Health Care, as CEO, from the brink of bankruptcy to one of the nation’s highest ranked health care providers.

Firdaus Bhathena is currently the Chief Digital Officer of CVS Health, and was formerly the Chief Digital Officer of Aetna, prior to the acquisition of Aetna by CVS Health. He is now responsible for the combined company’s digital strategy, products, platforms, consumer engagement, and operations. CVS Health’s mission is to be the most consumer-centric health company in the world, and Firdaus and his team are focused on delivering the integrated market-leading digital experiences that will revolutionize health and well-being for consumers everywhere, enabling them to lead happier, healthier, and more productive lives. He also plays a leadership role in establishing and executing on key partnerships with leading technology and consumer product companies, and for analyzing the competitive environment to fine-tune the company’s digital strategy. Firdaus has extensive experience in technology entrepreneurship and delivering world-class enterprise and consumer software products at scale. He was the co-founder of venture-backed software startups that were acquired by Cisco Systems and Symantec, and went on to lead high-performance distributed software product organizations at both acquirers. He has nine patents in software and distributed systems to his name, and has worked on projects as diverse as data-center application management, secure electronic communication, electricity power grid optimization, and consumer photo-video management. Firdaus earned BS and MS degrees in Electrical Engineering and Computer Science, both from the Massachusetts Institute of Technology (MIT) in Cambridge, MA, where he was a Henry Ford II scholar for “exceptional potential for leadership in technology.” He also won the MIT $50K Entrepreneurship Business Plan Competition.

Amitabh Chandra is the Henry and Allison McCance Professor of Business Administration at Harvard Business School and the Ethel Zimmerman Wiener Professor of Public Policy and Director of Health Policy Research at the Harvard Kennedy School of Government. Professor Chandra is a member of the Congressional Budget Office's (CBO) Panel of Health Advisors, and is a Research Associate at the National Bureau of Economic Research (NBER). His research focuses on innovation and pricing in the biopharmaceutical industry, value in health care, medical malpractice, and racial disparities in healthcare. His research has been supported by the National Institute of Aging, the National Institute of Child Health and Development, the Robert Wood Johnson Foundation, and has been published in the American Economic Review, the Journal of Political Economy, the New England Journal of Medicine, the Journal of the American Medical Association, and Health Affairs. He is the Chair Editor of the Review of Economics and Statistics. Professor Chandra is an elected member of the National Academy of Medicine, the first-prize recipient of the Upjohn Institute's Dissertation Award, the NIHCM Foundation Health Care Research Award, the Kenneth Arrow Award for best paper in health economics, and the Eugene Garfield Award for the impact of medical research. In 2012, he was awarded American Society of Health Economists (ASHE) medal. The ASHE Medal is awarded biennially to the economist age 40 or under who has made the most significant contributions to the field of health economics.

Tanzeem Choudhury is CEO and co-founder of HealthRhythms Inc., a company whose mission is to add the layer of behavioral health into all of healthcare. She is also a professor at Cornell/Cornell Tech and the director of the People-Aware Computing group, which works on inventing the future of technology-assisted wellbeing. Tanzeem is an internationally-acclaimed pioneer in behavior sensing technology. She obtained her Ph.D. from the MIT Media Lab. As part of her doctoral work, Choudhury created the sociometer and conducted the first experiment that uses mobile sensors to model social networks, which led to a new field of research referred to as Reality Mining. She has successfully created bridges between computer science and health sciences to enable richer and more continuous analysis of people. Her work has influenced and shaped the field of mobile health tracking and intervention. Tanzeem has been awarded the prestigious MIT Technology Review TR35 award, TED Fellowship, Kavli fellowship, and ACM Distinguished Membership.

Dr. Colón brings over 25 years of experience in biopharma, genomics, healthcare and industrial biotechnology. In addition to her role at InCarda, she serves on the board of directors of ProterixBio (Executive Chairman; formerly CEO), CareDx (NASDAQ:CDNA) and Cocoon Biotech, and formerly on the boards of Paradigm Diagnostics and PerceptiMed. She was also formerly a Partner and Senior Advisor at New Science Ventures, a NY-based venture capital firm with over $700M under management, and held executive and managerial roles at Intrexon Corporation, Gilead Sciences, Affymetrix, the International Genomics Consortium and McKinsey & Co. Dr. Colón received her Ph.D. from the Massachusetts Institute of Technology and a B.S. degree from the University of Pennsylvania, both in chemical engineering.

Hans Constandt has a bachelor in medicine, master in biotechnology and information sciences and worked three years at the University of Ghent as postgraduate in bioinformatics. He was active as a senior IT analyst and data architect for multiple small and big companies integrating new strategies for data integration and digital change. Hans worked eleven years at Eli Lilly as account manager, global senior business consultant, and global knowledge management lead for multiple domains and departments delivering portfolio analysis tools using linked data and semantic search. Hans completed a master in innovation and entrepreneurship at the Vlerick management school and an entrepreneurial accelerator track at MIT, engaging in several startups as a founder, mentor, board member, and advisor. Hans believes strongly in the principles of open data and FAIR data and is a linked data evangelizer participating in many hackathons, panels, talks and workshops worldwide. He's a passionate entrepreneur and avid speaker believing smarter data can truly change lives in the field of life sciences, healthcare and beyond. Up till now, he founded three companies and is active in four other companies where he is on a mission to digitally transform companies, industries, and some paradigms along the way. Hans has won many rewards with his company ranging from "Gartner Cool Vendor" to winning the "EY scale-up of the year 2018" across all European startups in all industries. He raised +10Mio Euro, is scaling up his company fast with global recognition and impact and aiming at tripling revenues every year.

Brett Davis is a Principal in Deloitte’s Life Sciences and Healthcare consulting practice and General Manager of ConvergeHEALTH by Deloitte, a business unit focused on supporting the information based transformation of healthcare and life sciences. In this role he is responsible for managing Deloitte’s $150M+ investment in new digital engagement and advanced analytics platforms to support the industry’s shift to value based, personalized healthcare. ConvergeHEALTH’s platforms are supporting organizations and patients in over 20 countries globally. In addition to his role at Deloitte, Davis serves on the External Advisory Boards of the Jefferson School of Population Health and the University of Pennsylvania’s Department of Medical Ethics and Health Policy. Previously he served as a Board member of the Personalized Medicine Coalition for 6 years, and as an external advisor to the Ben and Catherine Ivy Cancer Foundation.

Piali De, PhD is a co-founder and CEO of Senscio Systems, a technology company whose vision is to be a leader in technology platforms that automatically make sense of varied and voluminous data to support informed decision-making. Prior to Senscio Systems, Piali was an Engineering Fellow at Raytheon’s Integrated Defense Systems. At Raytheon, she developed a system called Confluence™, designed to deliver knowledge-based decision support for public safety missions, pandemic crisis, natural disaster responses, military missions, and situations that require multiple organizations to analyze data simultaneously and respond in immediate unison. Piali is the co-inventor of Senscio’s patented Scio™ framework, the artificially intelligent inference engine that contextualizes data in any domain into actionable intelligence. She is also the co-inventor of Ibis™ a health management system built upon Scio. Piali earned her Bachelors and Masters degrees in Physics from Hunter College of the City University of New York, with Summa Cum Laude honors, and a Ph.D in Physics from Brown University. She is a member of Phi Beta Kappa, Sigma Xi and Sigma Pi Sigma honor societies and is the recipient of the National Women of Color’s 2009 Technology Innovation award. In 2005, Piali received the Raytheon CEO Award, Raytheon IDS President’s Award and Raytheon Business Development Excellence Award, for her work on profiling Marine Corps missions.

Jay Desai is CEO & Co-Founder of PatientPing, a healthcare technology company that connects thousands of providers across the nation through real-time notifications and patient insights to seamlessly coordinate patient care. As a devoted healthcare reformer, Jay has spent his career creating tools to transform the healthcare system into one that provides higher quality care at lower costs. His passion lies at the intersection of technology, policy, and community building. In his role as CEO & Co-Founder, Jay sets the vision and mission for PatientPing and challenges his team of innovators and experts to change the way healthcare is delivered through light-weight and simple solutions. Jay has spent the past decade as a health care policymaker, young executive, and investor. Prior to co-founding PatientPing, Jay worked at the Center for Medicare and Medicaid Innovation where he helped design and implement ACO, Bundled Payment, and other innovative payment models that would become the cornerstones Affordable Care Act. While in this position, he was struck by the gaps in communication between providers. PatientPing was born out of his desire to find a simple solution that would transform the way providers would collaborate together on their shared patients. Jay’s previous experience includes Triad Isotopes, Parthenon Capital, and Lehman Brothers. He has served as a subject matter expert on health reform for a variety of provider organizations and co-founded the Health System Transformation Task Force. Jay earned an MBA in Health Care Management from the University of Pennsylvania’s Wharton School, a BBA from the University of Michigan, and is a Coro Fellow. When he’s not working to solve the hardest problems in healthcare, Jay can be found in his running shoes on Storrow Drive or walking his dog!

Christina Farr is a San Francisco-based award winning journalist with experience as an editor, beat reporter, writer and speaker. She covers the intersection of health and technology, exploring how recent policy changes have opened up both opportunities and risks for Silicon Valley. She is currently a senior writer covering health and technology for CNBC. She has freelanced for such publications as USA Today, Mashable and the Telegraph, and her work for Reuters appeared in the New York Times and Yahoo News. She was raised in London, UK, and received graduate degrees from University College London and Stanford University. Specialties Apple, Electronic Medical Records, Health IT, Longevity, Genetics, Startups, Venture Deals. Broadcast and Print Media.

Mariya Filipova leads Anthem’s Innovation function and oversees a network of ecosystem hubs across the country. She also leads a portfolio of initiatives that accelerate Anthem’s transformation into an AI-first company taking full advantage of exponential technologies and new business models. Mariya’s past experience as an entrepreneur and wall street analyst has shaped her perspective on transformation in closely regulated industries in Europe and the United States. She is a trusted advisor to both healthcare veterans and new entrants, from established industry leaders to start-ups in e-commerce, retail, and tech. Mariya previously led Deloitte’s global Future of Work Program Office, a portfolio of investments that use exponential technologies (e.g. blockchain, artificial intelligence) to redefine the way we do and monetize work.  She holds an MBA from Harvard Business School and a BA in Economics, summa cum laude, from Mount Holyoke College. She remains active in her alumni community where she serves on the Board of Governors for the Harvard Business School Association of Boston. She is currently based in Boston, MA.

During Bill’s more than twenty-year tenure investing in young and emerging healthcare technology companies, he has served on the Boards of numerous industry-leading companies and played a critical role, actively helping and working closely with founders and management. His current firm’s healthcare investments include Aetion, Bright Health, ClearDATA, Curisium, HealthReveal, Intauleca, Valence Health (Evolent Health), and VisitPay. Prior to Flare Capital, Bill was at North Bridge Venture Partners since its inception in 1994. Previously, Bill was a Partner at Hambro International Equity Partners. Prior to that, he was Chief Financial Officer at MathSoft, a science and engineering applications software start-up that went public on the NASDAQ and was later acquired by a leading design and product lifecycle software solutions company, and was a CPA at Arthur Andersen & Company. Bill received a B.S. degree from Boston College and has served his alma mater in a variety of capacities, including former Chair of the Board of Trustees and current member of its Investment and Endowment Committee. He has been Chair of the Parents Committee of Duke University and Chair of the Stanford University Parents Advisory Board. Additionally, Bill is an appointee of Massachusetts Governor Charlie Baker to the Oversight Council of the Center for Health Information and Analysis, serves on the Advisory Council of the Department of Biomedical Informatics, the Discovery Council at Harvard Medical School and was selected by the Deputy Secretary of Health and Human Services to serve on the federal department’s innovation and investment summit.

Luba Greenwood is a distinguished executive, investor, and company builder with over 20 years of leadership in healthcare and technology, and extensive global board experience. She is the CEO of Gallop Oncology, a clinical stage biotech. She has founded and served as Managing Partner of Dana Farber Cancer Institute venture fund, and CEO and board chair of multiple life sciences companies including Kojin Tx. She is an Entrepreneur-in-Residence at PureTech, where she plays a key role in advancing oncology programs. Luba has a proven track record of building world-class teams and companies, leading over $15B in deals and investments across therapeutics, diagnostics, and life sciences globally. She has held leadership roles at Google (Verily) and Roche, where as VP of Global Business Development & M&A, she spearheaded diagnostics BD and established the East Coast Innovation Hub. Recognized as an industry thought leader, she advises CEOs of top academic institutions, including Dana-Farber Cancer Institute and Wyss Center. She serves on the Investor Committee for National Cancer Institute and contributes to NEJM Catalyst. Luba is a strategic leader in digital transformation, AI, M&A, financing, and governance, with expertise in scaling companies, guiding high-impact transactions, and driving innovation at the intersection of biotech and technology. A former lawyer at WilmerHale, Luba is an expert in regulatory, IP, and corporate law. She has served as a Harvard University lecturer and sits on multiple public and private boards, including In8Bio, BenchSci, Stalicla, Abcam (where she led its sale to Danaher), Closed Loop Medicine, and MassBio.

John D. Halamka, M.D., leads innovation for Beth Israel Lahey Health. Previously, he served for over 20 years as the chief information officer (CIO) at the Beth Israel Deaconess Healthcare System. He is chairman of the New England Healthcare Exchange Network (NEHEN), and a practicing emergency physician. He is also the International Healthcare Innovation professor at Harvard Medical School. Dr. Halamka completed his undergraduate studies at Stanford University, where he received a degree in medical microbiology and a degree in public policy with a focus on technology issues. He entered medical school at the University of California, San Francisco and simultaneously pursued graduate work in bioengineering at the University of California, Berkeley focusing on technology issues in medicine. He completed his residency at Harbor–UCLA Medical Center in the Department of Emergency Medicine. As the leader for innovation at the $7 billion Beth Israel Lahey Health, he oversees digital health relationships with industry, academia, and government worldwide. As a Harvard professor, he has served the George W. Bush administration, the Obama administration, and national governments throughout the world planning their healthcare IT strategy. In his role at BIDMC, Dr. Halamka was responsible for all clinical, financial, administrative, and academic information technology, serving 3,000 doctors, 12,000 employees, and 1,000,000 patients. Dr. Halamka has authored a dozen books about technology-related issues, hundreds of articles and thousands of posts on the popular Geekdoctor blog. He runs Unity Farm in Sherborn, MA and serves as caretaker for 250 animals, 30 acres of agricultural production and a cidery/winery.

Dr. Iya Khalil is a technology entrepreneur and physicist with a vision of transforming medicine and healthcare into a discipline that is quantitative, predictive, and patient-centric via AI and big data. She co-founded two AI and machine learning companies, Gene Network Sciences Inc. and GNS Healthcare, and is the co-inventor of the proprietary AI and machine learning software platform that underpins both entities. Dr. Khalil’s machine learning and AI expertise spans 18 years with applications in drug discovery, drug development, clinical trial optimization, real world evidence and pharmaceutical commercial applications, and all the way to treatment algorithms that can be applied at the point of care. She is a frequent speaker at industry conferences including Exponential Medicine, Milken Global Conference, Health 2.0, SXSW, Bio, and TEDX and was recently profiled in Forbes Magazine as one of the women making artificial intelligence more accessible and less scary. Dr. Khalil has published extensively in AI and machine learning for healthcare, including peer-reviewed journal articles and poster presentations at scientific conferences such as ASCO, AACR, ASH, ISPOR and EASL. She was recognized by President Obama in 2014 as a leading entrepreneur in genomic medicine and more recently named to Inc’s magazine list of top female founders of 2018. Iya received her PhD and MS in Physics from Cornell University. In her spare time, she loves to advise early startups, spend time with her family and friends, travel, cook Libyan cuisine, enjoy the outdoors and is also fluent in Arabic. She is also a passionate member of Springboard enterprises, the largest network of innovators, investors and influencers who are dedicated to building high-growth women led technology companies.

Dr. Maricich leads the Clinical/Regulatory team at Pear Therapeutics as the Chief Medical Officer and Head of Clinical Development. He leads and manages the clinical development programs from Discovery/TPP to Therapeutic, Translational, Clinical Development, through Regulatory submission and prosecution. In addition to overseeing subsequent pipeline programs, including reSET-O (1st drug/software combination), Dr. Maricich leads Medical Affairs. Dr. Maricich is a licensed, board-certified physician, investor, clinical developer and strategist. He works to improve patient health and our healthcare system by providing care, investing in, advising, and providing leadership at innovative firms. He has worked with and lead successful teams and programs at Healthcare & Life Science/biotech (HLS) firms, including Corixa (acquired by GlaxoSmithKline), Xdynia (acquired by Cavion), Cavion, AWS, and Pear Therapeutics (1st FDA-cleared, clinically validated digital therapeutic to treat disease) and maintains clinical practice. He founded a digital health firm while a 3rd year med student that used AI and NLP to structure clinical data. Dr. Maricich earned his M.D. degree at the University of Washington School of Medicine, M.B.A from Harvard University, and his undergraduate at the University of Notre Dame. He completed internal medicine training at the University of Virginia Health System.

John is currently ranked as the #1 global influencer in digital health and generally regarded as one of the top global strategic and creative thinkers in this important and expanding area. His focus is on guiding companies, NGOs, and governments through the dynamics of exponential change in the health / tech marketplaces. A leading voice in the convergence of technology and health, Nosta helps define, dissect and deliberate global trends in digital health. He is consistently ranked among the top names in almost every digital health list and has sustained that position for several years. He is also a member of the Google Health Advisory Board. Further, John is also a frequent and popular contributor to Fortune, Forbes, Psychology Today and Bloomberg. In 2018, he received a PhD, honoris causa from Udabol Internacional: Oficial Universidad de Aquino Bolivia and from the Latin America Foundation, University of Science and Informatics Peru and Centre for Neuroscience. He was awarded the diploma of honour from the Bolivian government for his work in health technology in promoting innovation and engagement around the world. Earlier in his career, John was a research associate at Harvard Medical School and has co-authored several papers with global thought-leaders in the field of cardiovascular physiology with a focus on acute myocardial infarction, ventricular arrhythmias and sudden cardiac death. John cut his teeth at the "big" agencies including Ogilvy CommonHealth, where he has held a series of positions including Chief Creative Officer, Chief Strategic Officer and unit President.

Lesley Solomon became Dana-Farber’s senior vice president and chief innovation officer in 2017. She has served as the founding executive director of Brigham and Women’s Hospital's Innovation Hub, and as director of strategy and innovation in the Brigham Research Institute. Ms. Solomon has more than 20 years of experience as an executive working in business development, strategy, and marketing at startups, early-stage, and large companies such as the Food Network, Barnes & Noble.com, and Yoga Works. She received her MBA from Harvard Business School and has a BA in English from Cornell University. She is a co-founder of the Food Allergy Science Initiative at The Broad Institute of Harvard and MIT, which brings together experts across disciplines to unlock the biology of food allergy and change the field to develop new treatments and more.

Steven Wardell advises digital health leaders on growth strategies, fundraising, trade sales, and strategic alternatives. He is the author of The Future of Digital Health and the producer of the DigitalHealth InvestorTalk show. He was the first Wall Street analyst focused on digital health and therapeutics, where he was named a Rising Star by Institutional Investor. Steven has also held senior positions at digital health companies Activate Networks, PatientKeeper, and Informed Clinical Sciences, and founded the Boston chapter of Health 2.0. You can follow him at Twitter.com/StevenWardell.